Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxysafflor yellow A injection for acute ischemic stroke (phase III, randomized, double-blind, placebo-controlled)
ChiCTR2000038701Phase 3Completed
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Feb 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Hydroxysafflor yellow A with Placebo (0.9% saline) (2 arms). Primary endpoint: Proportion of subjects with mRS score ≤1 at 90 days. Started Feb 2020; status: completed.
02
Drugs
hydroxysafflower yellow a
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2000038701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038701.